Medicare Part D Is Changing Again in 2027. Here’s What Your Prescriptions Could Cost

Medicare prescription drug coverage is entering another year of major adjustment. The Inflation Reduction Act has already eliminated the old Part D coverage gap, reduced what beneficiaries can spend on covered prescriptions before reaching catastrophic coverage and capped the cost of covered insulin products. For 2027, however, the standard Part D deductible rises to $700 and the annual out-of-pocket threshold increases to $2,400, meaning retirees still need to pay close attention to how their individual plan handles medications.

Those headline numbers tell only part of the story. Medicare Part D is delivered through private insurance plans, and each plan can have a different formulary, premium, pharmacy network and cost-sharing structure within federal rules. One retiree may pay only a few dollars for a generic medication while another taking a specialty drug can reach the annual out-of-pocket threshold quickly.

That makes prescription coverage one of the least useful areas for choosing Medicare based on premium alone. A plan that costs $5 per month can ultimately be more expensive than one charging $40 if the cheaper plan places an important medication on a higher tier or excludes a preferred pharmacy. The best Part D plan is therefore the one that works with the drugs someone actually takes, not necessarily the one with the lowest advertised price.

Medicare Does Not Cover Every Drug Under Part D

Prescription coverage begins with understanding which part of Medicare is paying for the medication. Drugs administered while someone is admitted to a hospital are generally handled through Medicare Part A as part of inpatient care. Certain drugs administered by doctors or other healthcare professionals in outpatient settings can instead fall under Part B.

Part D primarily covers outpatient prescription medications that beneficiaries obtain for themselves through pharmacies or other participating providers. Someone enrolled in Original Medicare can purchase a stand-alone Part D prescription drug plan, while many Medicare Advantage plans include prescription coverage directly in the plan.

That distinction becomes particularly important for expensive medications. A drug infused in a physician’s office may fall under Part B, while a pill taken at home for the same condition could be covered through Part D. The beneficiary’s financial responsibility can therefore depend not only on the medication but also on how and where it is administered.

Retirees undergoing cancer treatment, autoimmune therapy or other expensive care should not assume every medication is governed by the Part D cap. The specific Medicare benefit responsible for the treatment should be confirmed before estimating the household’s potential drug costs.

Every Part D Plan Has Its Own Drug List

A Part D formulary is the list of medications the insurance plan agrees to cover. Medicare requires plans to meet federal coverage standards, but it does not require every plan to cover every drug in exactly the same way. Formularies can therefore vary meaningfully from one insurer to another.

That is one reason a beneficiary can have an excellent experience with one plan while a neighbor taking different prescriptions dislikes it. The plan may cover one person’s entire medication list inexpensively while placing another person’s important drugs on higher tiers or requiring additional approvals.

A large formulary does not automatically mean a plan is better, nor does it necessarily mean the premium will always be higher. The practical question is whether the plan covers the particular medications the beneficiary expects to use and what conditions are attached to that coverage.

Formularies can also change from year to year. A drug that was comfortably covered in 2026 may move to another tier or face new utilization restrictions in 2027. That is why an annual review remains worthwhile even when prescriptions themselves have not changed.

Drug Tiers Can Matter More Than the Premium

Most Part D plans divide covered medications into tiers, with lower-cost generics typically appearing in lower tiers and more expensive brand-name or specialty medications placed higher. Medicare notes that drugs in lower tiers generally cost less than those in higher tiers, although individual plan structures vary.

A lower-tier medication might require a fixed copayment, while a specialty drug may require coinsurance equal to a percentage of the negotiated price. That distinction can make an enormous difference. Paying 25% of a $20 generic is trivial compared with paying a percentage of a medication costing thousands of dollars.

This is why retirees should examine the actual cost-sharing language rather than simply whether a medication appears on the formulary. A covered drug can still be expensive, particularly when the plan uses coinsurance instead of a fixed copayment.

The annual out-of-pocket threshold limits how much beneficiaries ultimately spend on covered Part D drugs, but getting there can still require several thousand dollars. A retiree should therefore know not only whether a prescription is covered but how quickly it could push spending toward that threshold.

The Pharmacy Can Change the Price Too

Part D plans can contract with pharmacies differently, including distinguishing between preferred and standard network pharmacies. A beneficiary may pay substantially less for the exact same prescription at one participating pharmacy than at another.

That pricing difference can surprise retirees who assume a pharmacy is either “in network” or “out of network.” A standard network pharmacy may still accept the plan but charge a higher copayment or coinsurance than a preferred location. Someone filling several prescriptions every month can accumulate meaningful additional costs simply by using the wrong participating pharmacy.

Mail-order options can add another variable. Certain plans offer lower costs for 90-day supplies through preferred mail-order arrangements, while others provide equally competitive pricing through retail pharmacies. Beneficiaries should compare both price and convenience rather than assuming one distribution method is universally cheaper.

A medication list should therefore be paired with a pharmacy list when comparing plans. Medicare’s Plan Finder can help estimate total annual costs using specific medications and pharmacy preferences rather than forcing beneficiaries to compare premiums in isolation.

Prior Authorization Can Matter as Much as Coverage

Seeing a drug listed on the formulary does not necessarily mean the prescription will be filled immediately. Medicare Part D plans can apply several utilization-management tools intended to control costs and promote appropriate use.

Prior authorization requires the plan to approve coverage before certain medications are dispensed. The prescriber may need to demonstrate that the drug is medically necessary or that the beneficiary meets specific clinical requirements. Medicare also allows beneficiaries and prescribers to request exceptions when the plan’s normal requirements are inappropriate for the patient’s situation.

Step therapy can require the patient to try a less expensive drug first before the plan agrees to pay for a more costly alternative. Quantity limits can restrict how much medication the plan covers during a particular time period, such as limiting a prescription to 30 tablets each month.

These rules can reduce unnecessary drug spending, but they can also create delays or administrative work for people already stable on a treatment. Anyone with a critical medication should therefore check utilization rules before enrolling rather than discovering them at the pharmacy counter.

The Donut Hole Is Gone

For years, Medicare beneficiaries had to understand four distinct Part D phases, including the infamous coverage gap known as the donut hole. That structure changed substantially beginning in 2025.

The Inflation Reduction Act eliminated the coverage-gap phase, leaving a three-phase standard benefit: deductible, initial coverage and catastrophic coverage. Once beneficiaries reach the annual out-of-pocket threshold, they enter catastrophic coverage and owe no additional cost sharing for covered Part D drugs for the rest of the year.

That is a meaningful improvement for people taking expensive medications. Under earlier versions of Part D, beneficiaries could continue owing significant amounts even after prescription costs became extremely high. The redesigned benefit places a much clearer ceiling on covered out-of-pocket drug spending.

The elimination of the donut hole also makes older Medicare articles and explanations increasingly unreliable. Anyone still describing a 2027 Part D plan as moving through a coverage gap is using an outdated structure.

The 2027 Deductible Is $700, Not $55

One figure in older or poorly summarized Medicare material deserves correction. The standard Part D deductible was not $55 in 2023. It was $505 that year, increased to $615 for 2026 and is scheduled to reach $700 in 2027 under the defined standard benefit.

Not every plan necessarily charges the full standard deductible. Some plans can offer lower deductibles or apply the deductible differently to certain tiers, but no standard plan can exceed the federal maximum applicable under the rules.

The increase from $505 in 2023 to $700 in 2027 is still significant. A beneficiary with several medications subject to the deductible may face more out-of-pocket spending early in the calendar year before regular plan cost sharing begins.

There are also important exceptions. The deductible does not apply in the same way to covered insulin products or ACIP-recommended adult vaccines under the Inflation Reduction Act protections.

The Out-of-Pocket Threshold Rises to $2,400

The biggest Part D improvement beginning in 2025 was the new annual limit on beneficiary out-of-pocket spending for covered drugs. The threshold started at $2,000 in 2025, rose to $2,100 in 2026 and increases to $2,400 in 2027.

That increase is not simply an arbitrary decision to make drug coverage less generous. CMS updates the threshold according to formulas established in law, including changes in average Part D drug expenditures. For 2027, CMS calculated a 13.65% annual percentage increase used in updating key Part D parameters.

Once qualifying out-of-pocket spending reaches $2,400 in 2027, the beneficiary enters catastrophic coverage and generally owes nothing further for covered Part D drugs during the rest of the year. That can provide enormous protection for someone taking a medication costing tens of thousands of dollars annually.

The cap still does not mean that every prescription expense counts toward the threshold. Drugs that are not covered by the plan or purchases made outside applicable Part D rules may not receive the same treatment. Beneficiaries taking expensive medications should verify exactly how spending is credited rather than simply assuming every pharmacy payment advances them toward $2,400.

Insulin and Vaccines Receive Special Protection

The Inflation Reduction Act created additional protections that operate separately from the general deductible and out-of-pocket structure. Covered insulin products remain subject to a monthly cost-sharing limit. For 2026 and later years, the maximum payment for a month’s supply is determined under a formula that includes $35 as one potential ceiling, with lower amounts possible depending on negotiated or Medicare drug-pricing values.

Certain adult vaccines recommended by the Advisory Committee on Immunization Practices and covered under Part D also carry no beneficiary cost sharing. The policy is designed to remove financial barriers for vaccinations such as shingles and other recommended preventive immunizations.

Those protections are especially important because vaccines and insulin historically produced significant out-of-pocket bills for some Medicare beneficiaries. The changes do not eliminate every prescription expense, but they remove two categories that previously created particularly frustrating costs.

Retirees should still verify that the drug or vaccine is covered under the appropriate Medicare benefit. A policy limiting Part D insulin cost sharing does not necessarily describe every medication someone with diabetes might use.

The Part D Penalty Is Not 40 Cents a Month

Another common misunderstanding involves the late-enrollment penalty. Medicare does not impose one flat penalty of roughly 40 cents per month. Instead, the penalty grows depending on how long the beneficiary went without Part D or other creditable prescription coverage.

Medicare generally adds 1% of the national base beneficiary premium for every full month someone was eligible for Part D but went 63 days or more without Part D or other creditable drug coverage. The resulting amount is generally added to the monthly premium for as long as the beneficiary has Medicare drug coverage.

For 2026, the national base beneficiary premium is $38.99. CMS has announced that the 2027 base beneficiary premium will be $41.33, meaning the underlying dollar amount used in future penalty calculations will change as well.

A delay of only one or two months may create a small monthly charge, but a delay lasting several years can produce a meaningful lifetime penalty. The real lesson is not that the penalty itself is enormous in every case. It is that an avoidable premium surcharge can remain for the rest of the beneficiary’s time in Part D.

Creditable Drug Coverage Can Let You Delay Part D Safely

Not everyone needs to enroll in Part D at 65. People who have other prescription insurance that qualifies as creditable coverage can generally postpone Part D without triggering the late-enrollment penalty.

Medicare defines creditable prescription coverage as insurance expected to pay, on average, at least as much as standard Medicare drug coverage. Examples can include qualifying employer or union plans, TRICARE, Indian Health Service coverage and Department of Veterans Affairs drug coverage.

The beneficiary should retain documentation establishing that the coverage was creditable. Employer and insurance plans generally provide notices indicating whether the prescription coverage meets Medicare’s standard, and those records can become important later when someone enrolls in Part D.

The critical deadline begins when creditable coverage ends. Medicare says going 63 days or more without Part D or other creditable prescription coverage can trigger the late-enrollment penalty. That makes coordinating retirement and employer coverage particularly important.

The Seven-Month Initial Enrollment Period Still Matters

Most people first become eligible for Medicare around age 65, and the Initial Enrollment Period generally spans seven months: the three months before the birthday month, the birthday month itself and the following three months. Part D enrollment should be coordinated with that Medicare timeline unless the beneficiary has qualifying creditable prescription coverage.

Someone continuing to work can face a more complicated decision because employer size, existing health insurance and prescription coverage can affect when Parts A, B and D should begin. The fact that someone remains employed does not automatically answer whether the drug coverage is creditable.

Beneficiaries entering Medicare after losing employer insurance can also have Special Enrollment Period protections. The precise deadlines should be checked before employer coverage terminates instead of assuming Medicare can always be added retroactively.

Late enrollment becomes particularly expensive when someone misunderstands the difference between having health insurance and having creditable prescription drug coverage. A medical policy can exist without automatically satisfying the Part D standard.

Open Enrollment Is the Time to Rebuild the Comparison

Medicare’s annual Open Enrollment Period runs from October 15 through December 7. During that period, beneficiaries can change Medicare Advantage and prescription drug arrangements for the following year.

Part D plans generally renew automatically if the plan remains available and the beneficiary takes no action. Automatic renewal is convenient, but it should not be confused with evidence that the plan remains the best choice.

Every fall, the plan sends an Annual Notice of Change describing modifications to premiums, cost sharing and coverage. A drug could move to a higher tier, a preferred pharmacy arrangement could disappear or the plan could change its deductible even while the overall product remains available.

The proper annual review is therefore very specific. Enter every prescription, dosage and preferred pharmacy into Medicare’s comparison system and look at estimated annual costs under each available plan. A premium difference of several hundred dollars can be irrelevant if another plan reduces spending on one expensive medication by several thousand.

The Cheapest Plan Can Become the Most Expensive Plan

Imagine one Part D plan costs $8 a month while another costs $45. The instinctive choice is the $8 option, saving more than $400 per year in premiums.

Now suppose the first plan places an important brand-name medication on a less favorable tier and uses coinsurance, while the second offers a modest copayment through a preferred pharmacy. The more expensive premium could easily produce the lower total annual cost.

That is why Part D should be evaluated using total expected spending: premiums, deductible, copayments, coinsurance and pharmacy pricing. A retiree taking no medications may reasonably place more weight on the premium, while someone managing multiple chronic conditions should focus heavily on the formulary.

The calculation can change every year because prescriptions and insurance designs change. Loyalty to a particular carrier does not guarantee loyalty from that carrier to the beneficiary’s current drug list.

The best Medicare prescription plan is consequently not a permanent choice. It is a one-year contract that deserves to be reexamined before the next one begins.

Part D Has Become Better Protection Against Catastrophic Drug Costs

The modern Part D program is substantially different from the one many retirees remember. The donut hole has disappeared, catastrophic cost sharing has been eliminated for beneficiaries, covered insulin receives special protection and the annual out-of-pocket threshold provides far greater certainty for people using expensive medications.

At the same time, the standard deductible has continued climbing and reaches $700 in 2027, while the out-of-pocket threshold rises from $2,100 to $2,400. Plans still control formularies, pharmacy arrangements and utilization rules within Medicare requirements, meaning individual experiences can vary considerably.

The resulting system is simultaneously simpler and more complicated. The benefit phases are easier to understand because the donut hole is gone, but selecting the right plan still requires detailed attention to medications, tiers and pharmacies.

For retirees, the most important habit is not memorizing every Part D number. It is recognizing that prescription coverage needs to be reviewed as carefully as medical insurance. A drug plan that worked perfectly this year can become an expensive mistake next year without ever changing its name.

The federal cap now provides meaningful protection against unlimited covered prescription costs. Everything below that cap, however, still depends heavily on choosing the plan that matches the medications someone actually takes.